NPY and osteosarcoma: Recently, the Y1 receptor was reported to be present in human osteoblastic and osteosarcoma-derived cell lines (Lundberg et al. 2007), and treatment of wild-type mice with NPY caused reduction in bone mass and volume (Ducy et al. 2000).